Kinarus Therapeutics Holding AG Reports Unaudited Financial Results for Fiscal Year 2023

Kinarus Therapeutics Holding AG, a Swiss company listed on the SIX Swiss Exchange and active in the development of therapeutic drugs, announced today, February 28, 2024, the publication of its unaudited financial statements for the fiscal year 2023. This This announcement precedes the Extraordinary General Meeting scheduled for March 1, 2024, during which various resolutions related to the planned business combination with Curatis AG will be discussed.

However, these financial statements remain unconsolidated and proprietary to Kinarus Therapeutics Holding AG, as Kinarus AG is currently in liquidation. Any modifications may be made to these documents until the publication of the audited financial statements.

Completion of the merger with Curatis AG is subject to the approval of the Extraordinary General Meeting of Kinarus Holding and other conditions set out in the transaction agreement. If these conditions are met, the closing of the business combination is scheduled for the end of April 2024.